Clinical Trial Update: Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients [Phase 2, Phase 3]

View source ↗

Summary

Prospective double-blind, placebo-controlled trial of omalizumab (Xolair) in chronic urticaria, spanning Phase 2 and Phase 3 cohorts.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria
• Spontaneous Urticaria
• Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Chronic Urticaria, Chronic Idiopathic Urticaria | Phase 2, Phase 3 | Status: COMPLETED